Early Design Decisions that Shape Medical Device Success with Chris Danek, CEO of Bessel | Ep. 63
This episode of the Med Device Cyber Podcast, hosted by Christian Espinosa and Trevor Slattery of Blue Goat Cyber, features guest Chris Danek, the Founder and CEO of Bessel. The discussion centers on the critical need for medical device startups to integrate cybersecurity into their product development process from the very beginning, rather than treating it as a late-stage compliance checkbox. Chris Danek, whose company specializes in helping medtech startups commercialize their innovations, frames the conversation around the concept of creating products with "breakthrough impact." The hosts and guest argue that achieving this impact in today's environment is impossible without a robust and proactive cybersecurity strategy, as neglecting it can lead to devastating financial and product-related consequences.
The core argument made throughout the episode is the reframing of medical device cybersecurity from a simple data protection issue to a fundamental component of patient safety. Christian Espinosa vividly illustrates this by describing worst-case scenarios, such as a hacked surgical robot causing paralysis or a compromised defibrillator delivering fatal shocks. This leads to a discussion of several key misconceptions prevalent in the industry. A major point of contention is the false assumption that software developers are inherently cybersecurity experts. Espinosa provocatively states that, in his experience, only about one in a hundred software developers truly understand cybersecurity, emphasizing that the skillset required to build software is fundamentally different from the adversarial mindset needed to secure it. This mistake often results in cybersecurity being pushed to the end of the development cycle, a practice the speakers deem a potential "product killer."
To avoid these pitfalls, the experts advocate for a comprehensive, lifecycle-based approach to security. Trevor Slattery highlights the immense costs of late-stage testing, recounting instances where thousands of vulnerabilities were discovered just months before a planned regulatory submission, causing delays and cost overruns exceeding half a million dollars. The solution, they propose, is to start with threat modeling at the conceptual stage to understand what could go wrong and how an attacker might compromise the device. This informs early architectural decisions, ensures security requirements are baked into the design, and guides the selection of secure hardware and software components. The conversation stresses that this proactive stance is not just about appeasing regulators like the FDA, but about de-risking the entire business venture, streamlining development, and ultimately delivering a safer and more effective device to market for the benefit of patients.
